Hungarian pharma grabs rivals for $1.5B

While all eyes were on other potential mergers, Hungary's Richter Gedeon made two deals that will boost it to the top of Central and Eastern Europe's pharma industry.

In a $1.32 billion buyout, Richter will acquire Poland's Polpharma, which went private in 2000 and has been growing ever since. At the same time, Richter will fork over $126.4 million for an 80 percent stake in Russia's OAO Akrihin. The deals will be done via stock swap with Genefar, which owns Polpharma and a stake in OAO Akrihin (the latter as part of an investor group). Thus Richter will grow to a market cap of $5.3 billion, and Genefar will end up with a stake of 26.75 percent.

The deals appear to be Richter's way of growing out of a slump. Because of budget-cutting in Hungary, Richter has seen domestic sales drop; in the third quarter, those revenues fell 24 percent. Post-buyouts, the company expects a quarter of its sales to come from Poland and another 20 percent from Russia, with only 20 percent sourced at home.

- check out this release on the buyout
- read the report from the Budapest Business Journal
- get more details from Monsters and Critics

Related Articles:
Tips for a successful biotech sector. Report
Who's next on the biotech buyout hit list? Report
Should Pharma take the M&A cure? Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.